<DOC>
	<DOCNO>NCT01884571</DOCNO>
	<brief_summary>This multicenter , 15-month study evaluate effect immunosuppression treatment rate change ALS Functional Rating Scale ( Revised ) ( ALSFRS-R ) score 33 subject Amyotrophic Lateral Sclerosis ( ALS ) .</brief_summary>
	<brief_title>Immunosuppression Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>In ongoing safety trial neural stem cell injection spinal cord patient ALS Emory University , Atlanta , Georgia , one patient demonstrate clear improvement objective clinical electrophysiological measure , find unheard patient ALS . This patient improvement ALSFRS-R 1.4 point per month . In 826 historical control Northeast ALS Consortium ( NEALS ) Western ALS Consortium ( WALS ) database ALSFRS-R document 2 visit , patient show improvement ALSFRS see case . Additionally , 5 patient stem cell trial mechanical ventilator time surgery seem slow disease progression compare expectation current understanding typical disease course . This observation raise consideration disease-modifying effect novel immunosuppression regimen use trial . Also , give ALS clinically extraordinarily heterogeneous disease , diagnosis ALS may represent group phenotypically similar pathogenically variable disorder . It possible exist subset patient immune-responsive ALS subtype previously recognize . Recent study further understanding immune mechanism contribute ALS progression . Microglia lymphocytes neurotoxic neuroprotective function depend activation state physiologic condition within nervous system . Therefore , target immunotherapy proportionally suppress neurotoxic immune element , spar promote protective element , seemingly potential modify disease course ALS previously test regimen . It postulate immunosuppression treatment give stem cell patient may exhibit neuroprotective effect favorably promote ratio regulatory T cell protective immune mediator relation neurotoxic immune modulators . It hop trial optimize chance replicate finding allow learn complex change occur within immune system patient ALS treatment immunosuppression regimen . The primary objective study assess clinical response rate novel immunosuppression regimen subset ALS patient . The primary outcome measure rate change ALSFRS-R. A clinical response define rate change ALSFRS-R +6 point 6 month period ( mean change +1 point per month ) . Secondary outcome measure include slow vital capacity ( SVC ) , grip strength , hand hold dynamometry ( HHD ) . The change rate progression clinical measure monitor look potential disease-modifying effect immunosuppression regimen . Blood cerebrospinal fluid immune system marker also study .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Group A Male female patient 1865 year age . ALS diagnose possible , laboratorysupported probable , probable , definite define revise El Escorial Criteria . Symptom onset ≤ 24 month screen visit . A score ≥38 Revised ALS Functional Rating Scale . Slow vital capacity ( SVC ) measure &gt; 80 % predicted gender , height age screening . Subjects must take riluzole least 30 day , stable dose riluzole least 30 day , prior screen visit ( riluzolenaïve subject permit study ) . Negative tuberculosis ( TB ) test within 3 month Screening Visit . Subjects medically able undergo lumbar puncture ( LP ) determine investigator ( i.e. , bleed disorder , allergy local anesthetic , skin infection near LP site ) . Capable provide informed consent follow study procedure . Women must able become pregnant ( e.g . post menopausal , surgically sterile , use adequate birth control method ) duration study . Women childbearing potential must negative pregnancy test screen nonlactating . Geographic accessibility study site . Group B Inclusion Criteria Male female patient age 18 older . ALS diagnose possible , laboratorysupported probable , probable , definite define revise El Escorial Criteria . Symptom onset &gt; 24 month screen visit . Subjects must take riluzole least 30 day , stable dose riluzole least 30 day , prior screen visit ( riluzolenaïve subject permit study ) . Negative tuberculosis ( TB ) test within 3 month Screening Visit . Subjects medically able undergo lumbar puncture ( LP ) determine investigator ( i.e. , bleed disorder , allergy local anesthetic , skin infection near LP site ) . Capable provide informed consent follow study procedure . Geographic accessibility study site . Women must able become pregnant ( e.g . post menopausal , surgically sterile , use adequate birth control method ) duration study . Women childbearing potential must negative pregnancy test screen nonlactating . Group A &amp; B Exclusion Criteria Prior use basiliximab , solumedrol , prednisone , tacrolimus mycophenolate mofetil within 30 day Screening Visit . Known allergy sensitivity basiliximab , solumedrol , prednisone , tacrolimus mycophenolate mofetil formulation one drug . Treatment immunosuppressant medication within 30 day Screening Visit . Active peptic ulcer disease . Any medical disorder would make immunosuppression contraindicate include , limited , human immunodeficiency virus ( HIV ) , tuberculosis , evidence active cytomegalovirus ( CMV ) infection . Subjects diaphragm pace system ( DPS ) . Women pregnant , breastfeeding , plan become pregnant next 12 month . Active drug alcohol use dependence , opinion site investigator , would interfere adherence study requirement . Use invasive noninvasive mechanical ventilation ( include Continuous Positive Airway Pressure ( CPAP ) Bilevel Positive Airway Pressure ( BiPAP ) ) part day night prior Screening Visit ( Group A ) . Exposure agent currently investigation treatment patient ALS ( offlabel use investigational ) within 30 day Screening Visit . Inability safely complete study activity base discretion site investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Immunosuppression</keyword>
	<keyword>ALS</keyword>
</DOC>